Clinical trials: Recurrent Tuberculosis
Recurrent Tuberculosis
Improving Retreatment Success (IMPRESS)
This is an open label randomized controlled clinical trial comparing two regimens for treatment of smear-positive pulmonary TB, among patients previously treated for TB.
- Trial name
- IMPRESS (NCT02114684)
- Testing
- moxifloxacin
- Where
- South Africa
- Volunteers
- 197 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
Refractory Pulmonary Tuberculosis
Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs
This study will determine whether a drug called pimonidazole hydrochloride shows areas of low oxygen in tuberculosis (TB)-infected lungs.
- Trial name
- NCT00374517
- Testing
- Pimonidazole hydrochloride
- Where
- 2 sites in South Korea
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Exogenous Reinfection of Tuberculosis in Taiwan
we hypothesize that exogenous reinfection is very important in the Taiwan endemic. Therefore, we design a series of studies to evaluate the individual contribution of exogenous reinfection and endogenous reactivation in the…
- Trial name
- NCT00173433
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Infertility, Female, Recurrent Implantation Failure
Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
The purpose of this study is to assess the efficacy, safety and tolerability of the 1-month regimen of three times weekly rifapentine plus isoniazid in improving fertility outcome in recurrent implantation failure (RIF) patients…
- Conditions
- Infertility, Female, Recurrent Implantation Failure, Genital Tuberculoses, Female, Genital Tuberculosis, Latent
- Trial name
- SCRIPT-LGTB (NCT04528277)
- Testing
- rifapentine plus isoniazid
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Huashan Hospital
Tuberculosis
Multi-Drug Resistant Tuberculosis in Korea
This study, conducted in Korea, will examine why some people are more susceptible to tuberculosis (TB) than others and why some strains of M tuberculosis (the bacteria that causes TB) are more difficult to treat or become…
- Trial name
- NCT00341601
- Where
- 2 sites in South Korea
- Volunteers
- 777 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent Tuberculosis
Vitamin D to Resolve Inflammation After Tuberculosis (ResolveD-TB)
This Strategic Research Project is a translational proof-of-concept study that will determine whether vitamin D3 has potential to prevent recurrent tuberculosis (TB), as indicated by enhanced resolution of pulmonary inflammation…
- Trial name
- ResolveD-TB (NCT03011580)
- Testing
- Fultium-D3
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Queen Mary University of London
Tuberculosis, Pulmonary
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
The 4-month daily regimen containing moxifloxacin (2HRZEM 7 / 2HRM7) of ICMR-NIRT was studied in 321 sputum positive pulmonary TB patients in a randomised clinical trial.
- Trial name
- NCT05047055
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- India
- Volunteers
- 550 people
- Sponsor
- Tuberculosis Research Centre, India
Tuberculosis (TB)
Tuberculosis (TB) Aftermath
TB Aftermath will compare effectiveness, cost-effectiveness and feasibility of two ACF strategies for detecting recurrent TB and provide evidence needed to implement and scale the preferred ACF strategy.
- Trial name
- NCT04333485
- Testing
- Home-based Active Case Finding (HACF), Telephonic Active Case Finding (TACF)
- Where
- India
- Volunteers
- 3,094 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Tuberculosis
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function.
- Trial name
- TB-MET-NAC (NCT07136987)
- Testing
- Metformin, N-Acetylcysteine (NAC) Treatment, Standard TB treatment
- Volunteers
- 1,104 people
- Sponsor
- Open Source Pharma Foundation
Tuberculosis
Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy
This is a cohort observational study investigating the rate of tuberculosis (TB) recurrence in adult patients who have completed TB therapy for Pulmonary TB (PTB) and are on highly active antiretroviral therapy (HAART).The…
- Trial name
- TRuTH (NCT01539005)
- Where
- South Africa
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
Pulmonary Tuberculosis
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030.
- Trial name
- NCT06727864
- Testing
- 4-month regimen (2HERZ/2HRE), 6-month (2HERZ/4HRE)
- Where
- 8 sites in Taiwan
- Volunteers
- 270 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Tuberculosis, Pulmonary
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups. H56:IC31 (investigational vaccine) Placebo 900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are…
- Trial name
- NCT03512249
- Testing
- H56:IC31
- Where
- 6 sites in South Africa, Tanzania
- Volunteers
- 831 people
- Sponsor
- International AIDS Vaccine Initiative
Prevention of TB Recurrence
Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
This is a Phase II/III trial with two groups of adults successfully cured of category 1 pulmonary TB receiving either VPM1002 or placebo.
- Trial name
- NCT03152903
- Testing
- VPM1002 (Recombinant BCG Vaccine)
- Where
- 10 sites in Bangladesh, India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.